Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -14191.20% is 10199% below its 5-year average of -137.79%, near the low end of its 5-year range (-14191.20%–62.35%).
1904.86% below its 12-month average of -707.84%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3539.21%.
NET PROFIT MARGIN
-14191.20%
NET PROFIT MARGIN AVG TTM
-707.84%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-137.79%
NET PROFIT MARGIN AVG 10Y
-334.33%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1904.86%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-10199.01%
CURRENT VS 10Y AVG
-4144.68%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Denali Therapeutics Inc.
Market Cap
$3.05B
Net Profit Margin
-14191.20%
TTM Avg
-707.84%
3Y Avg
0.00%
5Y Avg
-137.79%
Market Cap
$3.09B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.04B
Net Profit Margin
6.15%
TTM Avg
-37.77%
3Y Avg
-2241.27%
5Y Avg
-1494.18%
Market Cap
$3.01B
Net Profit Margin
0.00%
TTM Avg
-172.68%
3Y Avg
-306.20%
5Y Avg
-1288.24%
Market Cap
$2.80B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.83B
Net Profit Margin
22.69%
TTM Avg
19.73%
3Y Avg
-2.42%
5Y Avg
-44.65%
Market Cap
$2.81B
Net Profit Margin
1.85%
TTM Avg
-5.88%
3Y Avg
-8.36%
5Y Avg
-6.41%
Market Cap
$3.40B
Net Profit Margin
33.42%
TTM Avg
30.07%
3Y Avg
2.48%
5Y Avg
-14.75%
Market Cap
$2.71B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.05B | -14191.20% | -707.84% | 0.00% | -137.79% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.04B | 6.15% | -37.77% | -2241.27% | -1494.18% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.01B | 0.00% | -172.68% | -306.20% | -1288.24% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.80B | 0.00% | 0.00% | 0.00% | 0.00% |
| TransMedics Group, Inc. (TMDX)vs › | $2.83B | 22.69% | 19.73% | -2.42% | -44.65% |
| AtriCure, Inc. (ATRC)vs › | $2.81B | 1.85% | -5.88% | -8.36% | -6.41% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.40B | 33.42% | 30.07% | 2.48% | -14.75% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | 0.00% | 0.00% | 0.00% | 0.00% |
| Celcuity Inc. (CELC)vs › | $3.45B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
-14191.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -3539.21% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | -7841.59% |
| 2023-06-30 | 62.35% |
| 2023-03-31 | -312.40% |
| 2022-12-31 | -959.62% |
| 2022-09-30 | -2902.47% |
| 2022-06-30 | -112.03% |
| 2022-03-31 | -154.77% |
| 2021-12-31 | -601.41% |
| 2021-09-30 | -1600.53% |
| 2021-06-30 | -264.58% |
| 2021-03-31 | -884.02% |
| 2020-12-31 | 77.30% |
| 2020-09-30 | -619.91% |
| 2020-06-30 | -1004.93% |
| 2020-03-31 | -1575.00% |
| 2019-12-31 | -1156.36% |
| 2019-09-30 | -340.05% |
| 2019-06-30 | -1389.97% |
| 2019-03-31 | -927.28% |
| 2018-12-31 | 61.69% |
| 2018-09-30 | -2959.92% |
| 2018-06-30 | -3320.63% |
| 2018-03-31 | -3693.92% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
